Related Experiment Video
Updated: Jun 29, 2025
09:14
Enzymatic Cascade Reactions for the Synthesis of Chiral Amino Alcohols from L-lysine
Published on: February 16, 2018
12.1K
Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)
Pierce V Kavanagh1, Folker Westphal2, Benedikt Pulver2,3
1Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Dublin, Ireland.
Drug Testing and Analysis
|April 3, 2024
Summary
1-dodecanoyl-LSD (1DD-LSD) is a novel psychedelic compound that produces LSD-like effects in mice, but with significantly lower potency than LSD. Its reduced efficacy suggests inefficient in vivo hydrolysis, potentially indicating a long-acting prodrug profile for future human studies.
Area of Science:
- Pharmacology
- Neuroscience
- Medicinal Chemistry
Background:
- 1-Acetyl-N,N-diethyllysergamide (ALD-52) is a psychedelic compound similar to LSD, acting as a prodrug.
- Novel lysergamides are synthesized to explore structure-activity relationships and have emerged as recreational drugs.
- 1-dodecanoyl-LSD (1DD-LSD) is a newly synthesized N1-acylated LSD derivative.
Purpose of the Study:
- To characterize 1DD-LSD analytically.
- To evaluate the in vivo psychedelic effects of 1DD-LSD using the mouse head-twitch response (HTR) assay.
- To compare the potency of 1DD-LSD with LSD and other related compounds.
Main Methods:
- Analytical characterization of 1DD-LSD.
- Administration of 1DD-LSD to C57BL/6J mice.
- Measurement of the head-twitch response (HTR) to determine median effective dose (ED50).
Main Results:
- 1DD-LSD induced the HTR in mice with an ED50 of 2.17 mg/kg (3.60 μmol/kg).
- LSD demonstrated 27-fold higher potency than 1DD-LSD in the HTR assay.
- 1DD-LSD was less potent than other N1-acylated lysergamides like ALD-52 and 1-propanoyl-LSD.
Conclusions:
- The lower potency of 1DD-LSD suggests less efficient in vivo hydrolysis compared to other N1-acylated lysergamides.
- Increased lipophilicity of 1DD-LSD may lead to sequestration in fat, reducing hydrolysis and prolonging effects.
- Further clinical studies are needed to assess 1DD-LSD's activity in humans and its potential as a long-acting prodrug for LSD.
